ADHD threshold levers — the drive-tone / arousal operating-point correction, decomposed into DNA-grounded levers (L3-only; the gain-amplitude core named, out of reach — the first PARTIAL fit in the series)

Chapter 22's gain/arousal ADHD substrate (intact wiring) maps onto the threshold frame and loads entirely on the up-stream drive lever (L3): five drive-tone genes, with both ionic-current levers empty. It is the first partial fit -- the dominant gain-amplitude core is named but out of reach, the wiring axis absent. Targets ranked, never drugs; not medical advice.

The ADHD-vs-autism chapter read ADHD not as a milder autism but as a different kind of fault entirely: a disorder of gain and arousal with the long-range wiring left intact. That intact wiring is the discriminant — it is what separates ADHD from autism, where a long-range connectivity axis was not only present but §19-proven unreachable. §22 grounded ADHD in an explicit gene substrate: a gain-amplitude (output) core — the catecholamine machinery that sets how much signal is made, released and cleared — and a smaller arousal / drive-tone set that sets where the firing level sits, with zero wiring genes and the axis-ambiguous / syndromic genes pre-registered out. This chapter applies the same piece of inherited technology the bipolar, epilepsy, depression, schizophrenia and autism levers chapters used — the threshold-shift intervention logic from the analgesic reproducibility package (Zenodo 10.5281/zenodo.20733420), whose three abstract levers are L1 change the inward (excitatory) current, L2 change the outward (potassium / inhibitory) current, L3 change the up-stream drive — and it produces the first PARTIAL fit in the whole series. ADHD is the sixth distribution pattern, and the most lopsided: it is L3-only. Of five lever genes, all five sit on the up-stream drive lever (L3: SLC6A3 the dopamine transporter, SLC6A2 the noradrenaline transporter, SLC6A4 the serotonin transporter, ADRA2A the α_2A-adrenergic receptor, and DRD4 the D₄ dopamine receptor) — and L1 and L2 are both EMPTY. That emptiness is itself the finding: ADHD is not a channelopathy; it has no ionic fold lever at all, only the [O] cited-biology drive surface where the stimulant, atomoxetine and guanfacine arms live (as directions, never doses). The fit is partial for a precise, two-sided reason. First, the dominant ADHD axis is out of reach: ADHD's core fault is the gain-amplitude axis — the catecholamine synthesis (TH, DBH), release (SNAP25) and catabolic clearance (COMT, a boundary node) machinery that sets signal amplitude — and a drive-tone (reuptake / receptor) lever has no handle on synthesis or release. The threshold frame reaches ADHD only through its secondary drive-tone axis and misses the dominant gain core, which is named with four real genes (carried with their own promoter reads alongside) but not reached. Second, the frame has no structural [F] grounding on ADHD at all — the [F] ionic levers L1/L2 are empty, leaving only the [O] drive surface. So the fit is graded [L] partial, the first and only non-clean fit across six disorders — and the partial grade is the finding, marking exactly where the cross-cutting threshold logic does and does not apply, refusing to overclaim a clean fit where the biology is a gain/arousal disorder. This is the precise inverse of autism: autism reached its dominant excitability axis and missed the output and wiring axes; ADHD reaches only its secondary drive-tone axis and misses the dominant gain axis, with no wiring axis at all. Each gene is placed by reading its own promoter switch stiffness — γ = −mean nearest-neighbour stacking free energy (SantaLucia 1998) over its promoter window, turned into |h_sp| = spinodal(γ) with the frozen engine read-only — and six of the nine reads (SLC6A3, DRD4, SLC6A4, TH, COMT from the depression / schizophrenia caches) are carried over verbatim, with ADRA2A, DBH and SNAP25 live GRCh38 strand-aware reads. The DNA reads carry an inversion that names itself: the stiffest promoter in the set, the dopamine transporter SLC6A3, is a reachable lever, while the softest, the SNARE release gene SNAP25, is an out-of-reach gain gene — the exact opposite of autism, where the stiffest reads were the out-of-reach genes. Three fail-closed disciplines ride along, and the forbidden-claim scanner is the strictest in the series: beyond the usual dose / efficacy / safety / synthesis classes it adds — uniquely for this stimulant topic — a stimulant-misuse class (it rejects get-high / snort / euphoria / recreational / party-drug vocabulary) and a cognitive-enhancement class (it rejects smart-drug / study-drug / nootropic / limitless framing), both negation-guarded. The firewall is absolute: the promoter |h_sp| is a gene's own switch stiffness, never a transporter occupancy, a synaptic catecholamine level, a stimulant's potency, a dose, or a clinical effect. efficacy = 0; not medical advice; ADHD is a difference in regulation, not a deficit of worth; the hard problem stays open.

the §22 ADHD gain/arousal substrate mapped onto the threshold-shift frame -- L3-ONLY (5 drive-tone levers; L1/L2 BOTH empty), the dominant gain-amplitude axis NAMED but out of reach, wiring ABSENT; the FIRST PARTIAL [L] fit in the series = the §22 adhd_axis_specific substrate (gain/arousal, intact wiring) is mapped onto the inherited L1/L2/L3 threshold frame by REACHABILITY and loads ENTIRELY on L3 (the up-stream catecholamine/monoaminergic drive): 5 drive-tone levers (SLC6A3/DAT, SLC6A2/NET, SLC6A4/SERT, ADRA2A/alpha-2A, DRD4/D4) with L1 and L2 BOTH EMPTY -- the 6th distribution pattern and the purest L3 case; the DOMINANT axis GA (gain-amplitude: catecholamine SYNTHESIS TH/DBH, RELEASE SNAP25, catabolic clearance COMT boundary) is NAMED with 4 real genes (gamma carried alongside) but explicitly NOT reachable by a drive-tone lever; W (wiring) is ABSENT (intact wiring, zero genes -- the discriminant from autism); the fit is PARTIAL [L], the FIRST and only non-clean fit across six disorders; targets ranked, never drugs or doses; no stimulant-misuse or cognitive-enhancement licence — the ADHD-vs-autism chapter (§22) proved ADHD is NOT a milder autism but a different fault: a disorder of GAIN and AROUSAL with INTACT WIRING -- an explicit gene substrate of six output/gain genes, two arousal/threshold genes, ZERO wiring genes (axis-ambiguous/syndromic genes FOXP2 and ADGRL3 pre-registered OUT to keep the 'intact wiring' discriminant airtight). This module applies the SAME threshold-shift intervention logic the bipolar, epilepsy, depression, schizophrenia and autism levers chapters used (inherited from the analgesic reproducibility package, Zenodo 10.5281/zenodo.20733420) to that substrate on the SAME R19 engine, READ-ONLY, with NO new mechanism and NO new tuned constant -- and it produces the FIRST PARTIAL [L] fit in the series. Mapped by REACHABILITY, ADHD is L3-ONLY: of 5 lever genes ALL 5 sit on L3 (the up-stream catecholamine/monoaminergic drive -- SLC6A3/DAT and DRD4/D4, §22-O gain genes reachable HERE as drive-TONE; SLC6A4/SERT and ADRA2A/alpha-2A, §22-T arousal tone; SLC6A2/NET, the atomoxetine arm extending the substrate), and L1 and L2 are BOTH EMPTY -- the 6th distribution pattern across the series (bipolar L1, epilepsy L1+L2, depression L3-dominant, schizophrenia L1+L3 co-dominant, autism L1-dominant) and the PUREST L3 case. The L1/L2 EMPTINESS is itself a finding: ADHD is NOT a channelopathy -- it has no ionic fold lever, only the [O] cited-biology drive surface (where the stimulant/atomoxetine/guanfacine arms live, as DIRECTIONS). The fit is PARTIAL [L] for a two-sided reason. (1) The DOMINANT ADHD axis is OUT OF REACH: ADHD is a GAIN/AROUSAL disorder, not a firing-FOLD disorder, and the threshold frame operates on the fold via an up-stream DRIVE lever, so it reaches ADHD only through the SECONDARY drive-tone surface and NOT through the GA gain-amplitude machinery (synthesis/release), which is the dominant fault -- the GA axis is NAMED with four real genes (TH rate-limiting catecholamine synthesis, DBH DA->NA synthesis, SNAP25 SNARE release output, COMT prefrontal catabolic clearance boundary), each carried with its own promoter gamma read ALONGSIDE but graded [F] NOT REACHED -- the autism O-axis named-out-of-reach discipline (§34), here applied to the DOMINANT axis. (2) A second sense of partial: the frame has NO structural [F] grounding on ADHD at all -- the [F] ionic levers L1/L2 are empty, leaving only the [O] drive surface. And W is ABSENT (intact wiring, zero genes) -- the discriminant from autism, which carried a W axis §19-PROVEN unreachable. This is the precise INVERSE of autism: autism REACHED its dominant axis (excitability) and missed O+W; ADHD reaches only the SECONDARY axis (drive-tone) and misses the DOMINANT axis (gain), with no W axis at all. Each gene's gamma = -mean(nearest-neighbour stacking dG, SantaLucia 1998) is read from its OWN promoter window (TSS-2000..+500, Homo sapiens) and turned into that promoter's switch stiffness |h_sp| = spinodal(gamma) and barrier = gamma^2/4 using the frozen engine READ-ONLY -- the identical pipeline the analgesic, bipolar, epilepsy, depression, schizophrenia and autism packages ran, and six reads (SLC6A3, DRD4, SLC6A4, TH, COMT from the depression/schizophrenia caches) are carried over VERBATIM (gamma is strand-symmetric, bit-identical), with ADRA2A, DBH, SNAP25 live GRCh38 strand-aware reads. The DNA reads carry an INVERSION that names itself: the STIFFEST promoter in the set, the dopamine transporter SLC6A3 (gamma~1.598, |h_sp|~0.778), is a REACHABLE drive-tone lever, while the SOFTEST, the SNARE release gene SNAP25 (gamma~1.438, |h_sp|~0.664), is an OUT-OF-REACH gain gene -- the exact opposite of autism, where the stiffest reads were the out-of-reach genes. Three fail-closed disciplines ride along: an L3-honesty gate keeps all five drive-tone links graded [O] cited biology (never derived) AND asserts L3 UNIQUE dominance, L1==L2==0 emptiness, the GA-axis named-out-of-reach, the W-axis ABSENCE, and the PARTIAL [L] grade; a forbidden-claim scanner -- the STRICTEST in the series -- rejects any dose/efficacy/safety/synthesis statement PLUS two stimulant-topic classes: a STIMULANT-MISUSE class (get-high/snort/euphoria/recreational/party-drug) and a COGNITIVE-ENHANCEMENT class (smart-drug/study-drug/nootropic/boost-focus/limitless), both NEGATION-GUARDED with planted self-tests that must fire; and a burden-weighted prioritisation ranks all 9 TARGETS with the gamma read carried alongside but NEVER folded into the score. The ADHD unmet-need signature is the INVERSE of autism's: ADHD HAS established core routes (DAT/stimulant, NET/atomoxetine, alpha-2A/guanfacine), so the reachable drive-tone transporters carry LOW unmet need (the LOWEST floor in the series), while the out-of-reach gain genes carry the unmet-need CEILING but are flagged not-actionable -- so the highest-burden targets (TH #1, DRD4 #2, DBH #3, SNAP25 #4) are all NON-actionable and the leading ACTIONABLE target SLC6A3/DAT sits only at #5 (lowered by its established-route low unmet). DECOUPLING (the firewall made visible, INVERSE of autism's): the stiffest promoter SLC6A3 sits at priority #5 not the top, while the top-priority TH has only the third-stiffest read. FIREWALL (non-negotiable): the promoter |h_sp| is the gene's own switch stiffness, NEVER equated with a transporter occupancy, a synaptic catecholamine level, a stimulant's potency, a dose, an in-vivo selectivity, or any clinical effect. Registered in run_all_atlas.py as the 13th atlas citizen (ADHD-T-L), reproducing bit-for-bit with engine byte-unchanged. medium_efficacy_tested=0; ranks targets not drugs; not medical advice; no stimulant-misuse or cognitive-enhancement licence; ADHD is a difference in regulation not a deficit of worth; hard problem OPEN. [L partial · O links]. this chapter

the §18-19 E/I over-excitation operating-point correction decomposed into a DNA-grounded three-lever target map (L1-dominant, L3-sparse, T-axis only; the out-of-reach O/W axes named and §19-proven) = the abstract over-excitation-correcting push of §18-19 is resolved into three concrete levers (L1 reduce inward glutamatergic/Na/Ca current -- DOMINANT, 5 targets; L2 increase outward K+ / restore GABA-A current, 4 targets; L3 remove the up-stream serotonergic drive -- SPARSE, 1 cautious [O] node) over 10 autism E/I genes placed by their own promoter switch stiffness, unifying the pre-existing autism_multilever_threshold.py under the formal L1/L2/L3 frame; the map reaches the excitability/threshold (T) axis ONLY -- the output-deficit (O) and long-range-wiring (W) axes are NAMED with six real genes but explicitly NOT reachable, and W-unreachability is PROVEN (not asserted) by §19; targets are ranked, never drugs or doses — the autism chapters (§18-19) proved autism is NOT one axis but three distinct fault axes -- T (excitability / E-I threshold, an over-excitation operating point whose ignition fold sits too low), O (synaptic gain / output deficit), and W (long-range wiring / connectivity) -- and that of these only the T axis is reachable by a scalar chemical lever, whose corrective SIGN is to REDUCE the excess drive / restore inhibition (raise the fold), the SAME direction as epilepsy/schizophrenia-positive. This module applies the SAME threshold-shift intervention logic the bipolar, epilepsy, depression and schizophrenia levers chapters used (inherited from the analgesic reproducibility package, Zenodo 10.5281/zenodo.20733420) to UNIFY the pre-existing autism_multilever_threshold.py (which carried the idea under informal A1/A2/A3 levers) into a DNA-grounded three-lever target map on the SAME R19 substrate, with NO new mechanism and NO new tuned constant. Autism is L1-DOMINANT with a nearly-empty L3 -- the 5th distribution pattern across the threshold-levers series (epilepsy L1+L2, depression L3, schizophrenia L1+L3 co-dominant, bipolar channel-led): of 10 lever genes, 5 sit on L1 (the excitatory-reduce axis GRIN2A, GRIN2B, GRIA1, SCN2A, CACNA1C), 4 on L2 (the inhibitory-restore axis KCNQ3, GABRB3, GABRA5, GABRA2), and just 1 on L3 (SLC6A4, a cautious non-monotone serotonergic node, graded [O]) -- the L3-sparsity is itself the finding that autism's actionable biology sits locally on the E/I set, with no clean up-stream drug drive. The TWO structural strengthenings beyond the schizophrenia domain-restriction template are: (1) the OUT-OF-REACH axes are NAMED with six real genes -- O (output/gain deficit) = SHANK3, SYNGAP1, NRXN1; W (long-range wiring/dysconnection) = CNTNAP2, RELN; plus the syndromic master MECP2 -- carried alongside the map but explicitly NOT levers (a gain-reducing scalar push would drive an output deficit LOWER, and cannot re-route geometry); and (2) the W-axis unreachability is PROVEN, not merely asserted -- §19 (autism_candidate_limits) showed a scalar threshold lever can only MASK the wiring fault via over-synchronisation (the seizure analogue: P5_threshold_lowering_is_mask_not_correction), never CORRECT it (P4_chemical_cannot_fix_W). Each gene's gamma = -mean(nearest-neighbour stacking dG, SantaLucia 1998) is read from its OWN promoter window (TSS-2000..+500, Homo sapiens) and turned into that promoter's switch stiffness |h_sp| = spinodal(gamma) and barrier = gamma^2/4 using the frozen engine READ-ONLY -- the identical pipeline the analgesic, bipolar, epilepsy, depression and schizophrenia packages ran, and seven reads (GRIN2A, GRIN2B, CACNA1C, GABRB3 from the schizophrenia cache, SCN2A, KCNQ3 from the bipolar cache, SLC6A4 from the depression cache) are carried over VERBATIM (gamma is strand-symmetric, bit-identical). Two honest caveats are recorded, not hidden: SCN2A and GRIN2B are GoF/LoF SIGN-SUBTLE (a gain-of-function pushes the early-infantile DEE/seizure pole while a loss-of-function pushes the milder ASD/ID pole -- opposite directions), and the T-lever pushed TOO HARD is itself the seizure edge (the real ASD+epilepsy comorbidity) -- exactly why gamma is graded [V] for promoter STRUCTURE only, trait-blind, with clinical direction [O]. Three fail-closed disciplines ride along: an L3-honesty gate keeps the serotonergic link graded [O] cited biology (never derived) AND asserts L1 UNIQUE dominance, L3 SPARSITY, the T-axis domain restriction, and the NAMED + §19-proven O/W out-of-reach axes; a forbidden-claim scanner rejects any dose, efficacy, safety or synthesis statement PLUS -- uniquely for this YMYL topic -- an autism QUACKERY class (chelation, MMS / miracle-mineral / chlorine-dioxide bleach protocols) and a NORMALISE-framing class that protects neurodiversity respect (autism is a neurodevelopmental DIFFERENCE, not only a deficit; the map never emits cure/normalise/fix-autism language), each with a planted self-test that must fire; and a burden-weighted prioritisation ranks TARGETS with the gamma read carried alongside as structural context but NEVER folded into the score. The AUTISM unmet-need signature is that there is NO approved CORE-feature pharmacology (only the irritability adjunct is licensed), so -- unlike schizophrenia where the established D2 route lowers DRD2's unmet need -- U stays uniformly HIGH, and the L2 INHIBITORY-RESTORE route surfaces as the cleanest ACTIONABLE direction precisely because the high-scoring L1 excitatory genes are GoF/LoF sign-subtle (SCN2A/GRIN2B) or cross-disorder set-points (CACNA1C); the stiffest promoter SLC6A4 sits LOWEST on priority and non-actionable while the top-priority GABRB3 reads mid-range, the decoupling that makes the firewall visible. FIREWALL (non-negotiable): the promoter |h_sp| is the gene's own switch stiffness, NEVER equated with the §18 network over-excitation fold (the E/I ignition threshold on R), nor with a receptor occupancy, a synaptic level, a drug's potency, a dose, an in-vivo selectivity, or a clinical effect. Registered in run_all_atlas.py as the 12th atlas citizen (ASD-T-L), reproducing bit-for-bit with engine byte-unchanged. medium_efficacy_tested=0; ranks targets not drugs; not medical advice; autism is a difference not only a deficit; hard problem OPEN. [V map · O links]. canonical §34

What §22 established (gain and arousal, with the wiring left intact)

The ADHD-vs-autism chapter did for ADHD what the autism chapters did for autism: it refused the single-dial picture and replaced it with a statement about which kind of fault ADHD is. Its result is sharp and it is the discriminant the whole of this chapter rests on: ADHD is a disorder of gain and arousal with the long-range wiring left intact. Two of those three words carry the load. Gain — the amplitude of catecholamine signalling, how much dopamine and noradrenaline is synthesised, released, and cleared — is the dominant ADHD axis. Arousal — the drive-tone, where the firing set-point sits — is a secondary axis. And intact wiring is the crucial negative: ADHD does not carry the long-range connectivity fault that defines autism's W axis. §22 grounded this in an explicit gene substrate: six output/gain genes (the catecholamine synthesis, release and clearance machinery), two arousal/threshold genes (the monoaminergic tone set), zero wiring genes, and the axis-ambiguous or syndromic genes — FOXP2 (a language-syndrome transcription factor) and ADGRL3 (an adhesion-GPCR that could smuggle a wiring fault) — pre-registered out, precisely so the ‘intact wiring’ discriminant stays airtight.

§22 also proved the behavioural consequence and stopped. The stimulant restores the ADHD gain axis to health — in both synchrony and θ–γ coupling — where the same stimulant only partly reaches autism, and the dose-cap's long-range benefit is several times larger where wiring is broken; on a composite AuDHD substrate the stimulant fixes the gain axis and the cap the wiring axis without interference. But §22 left the molecular handle abstract. It said ADHD is a gain/arousal disorder and that a stimulant restores it; it did not resolve that restoration into concrete levers on the operating point, name the genes each lever touches, place those genes by their own DNA, or — the point that makes this the first partial fit — ask honestly whether the cross-cutting threshold-shift logic even reaches the dominant axis. A mechanism atlas should be able to say which molecular targets realise the reachable correction and be honest, by name, about the axis the lever frame cannot touch. That is exactly what this chapter does — and unlike the five chapters before it, the honest answer is that the frame catches the secondary axis and misses the dominant one.

The inherited technology, applied a sixth time — and the L3-only pattern

The handle is not invented here. It is the same threshold-shift intervention logic the bipolar, epilepsy, depression, schizophrenia and autism chapters inherited from the analgesic reproducibility package (Zenodo 10.5281/zenodo.20733420). Its premise is general: an operating point is set by a balance of currents and the drives that bias them, so there are exactly three levers on it. L1 — change the inward, excitatory current. L2 — change the outward, repolarising (or inhibitory) current. L3 — change the up-stream drive that sets where the operating point sits. The frame applies unchanged because the ADHD substrate, the five levers chapters, and the analgesic package all share the same R19 substrate — the engine's supercritical pitchfork ṣ = g·s − s³ + h, whose spinodal fold IS the switching barrier. Nothing about the engine is touched; the module re-emerges the frozen tree read-only, confirms it byte-unchanged, and registers as the thirteenth atlas citizen (ADHD-T-L).

ADHD is the sixth distribution pattern across the series, and by far the most lopsided. Where bipolar leaned on L1 (calcium channels), epilepsy on L1+L2 (the KCNQ2/KCNQ3 M-current), depression on L3 (the up-stream HPA / monoamine / neurotrophic drives, L3-dominant but with a reachable L1/L2 mix), schizophrenia on L1+L3 co-dominantly, and autism on L1-dominant with a sparse L3, ADHD is L3-only: of the five lever genes, all five sit on L3, and L1 and L2 are both empty. This is the purest L3 case in the atlas, and the emptiness of L1 and L2 is not a gap in the search — it is a structural fact. ADHD's actionable biology is the up-stream catecholamine and monoaminergic drive: the reuptake transporters and the tone receptors, exactly where ADHD pharmacology lives. There is no ionic fold lever — no channel whose inward or outward current you would change to raise or lower a firing threshold — because ADHD is not a channelopathy. The pipeline is reused at the level of code, not analogy: six of the nine reads — SLC6A3, DRD4, SLC6A4 on the lever side and TH, COMT on the out-of-reach side (and SLC6A4 again) — are carried over verbatim from the depression and schizophrenia caches, because γ is a strand-symmetric property of the sequence and does not change between problems; only ADRA2A, DBH and SNAP25 are fetched fresh (GRCh38, strand-aware).

The first partial fit: why the dominant axis is out of reach (and the discriminant that wiring is absent)

This is the result that makes ADHD the most structurally honest chapter in the levers series, and the first that does not produce a clean fit. The five chapters before it produced clean [V] fits: bipolar, epilepsy and depression mapped fully onto the frame, and schizophrenia and autism were domain-restricted but exact on the axes they reached. ADHD is different, and the module says so in a partial-fit witness that grades the fit [L] partial. The reason is two-sided. The first and decisive sense: the dominant ADHD axis is out of reach. ADHD is a gain / arousal disorder, not a firing-fold disorder. The threshold-shift frame operates on the fold via an up-stream drive lever (L3), so it reaches ADHD only through the drive-tone surface — the reuptake transporters and tone receptors, the secondary axis — and not through the gain-amplitude machinery (synthesis and release), which is the dominant fault. A reuptake / receptor lever has no handle on how much transmitter is made or released; it can only modulate the tone of what is already there. So the frame catches the secondary set-point but not the dominant gain core, and the fit is partial. The second sense: even on the reachable side, the frame has no structural [F] grounding on ADHD — the [F] ionic levers L1 and L2 are empty, leaving only the [O] cited-biology drive surface. Either way the conclusion is the same: [L], not [V]. The partial grade is the finding, not a failure — it marks exactly where the cross-cutting threshold logic does and does not apply, and it refuses to manufacture a clean fit on a biology that is fundamentally about amplitude rather than threshold.

The second strengthening is the discriminant, and it is the cleanest way to state what separates ADHD from autism. ADHD's wiring axis is absent. Where autism carried a long-range W axis that was not only present but §19-proven unreachable, ADHD has zero wiring genes — the module records W: present_in_disorder = false, named_genes = []. ADHD has intact wiring; there is no connectivity fault to name, reach, or fail to reach. This is the precise inverse of autism, and the module spells the inversion out: autism's lever map reached its dominant axis (excitability) and missed the output and wiring axes; ADHD's lever map reaches only its secondary axis (drive-tone) and misses the dominant gain axis, with no wiring axis at all. Autism was a clean fit that was domain-restricted; ADHD is the first partial fit, and the partiality lands on the dominant axis. The module captures all of this in a domain-restriction witness (DT = reached, GA = named but not reached, W = absent) and an out-of-reach-targets section that lists the four gain genes by name — making the partiality concrete, axis-structured and gene-named rather than a vague hedge, which is far more informative than a map that pretended to cover the whole disorder.

L3 is the whole map — the five drive-tone levers (ADHD pharmacology as directions)

The entire reachable map is the up-stream drive lever, and it carries five genes — the transporters and receptors that set the tone of catecholamine and monoamine signalling. SLC6A3 is the dopamine transporter (DAT), the reuptake pump that sets ambient dopamine tone — the canonical methylphenidate / amphetamine target, and a §22 gain-axis gene that is reachable here as a drive-tone node (a transporter modulates tone, not synthesis). SLC6A2 is the noradrenaline transporter (NET), the reuptake partner of DAT and the atomoxetine arm — it extends the §22 substrate onto the noradrenergic reuptake route. SLC6A4 is the serotonin transporter (SERT), carried as a §22 arousal / E-I tone node. ADRA2A is the α_2A-adrenergic receptor, the noradrenergic arousal receptor and the guanfacine arm. And DRD4 is the D₄ dopamine receptor, a §22 gain gene reachable here as a drive-tone node because a receptor reads dopaminergic drive. These are the three real-world ADHD pharmacological routes — the stimulant (DAT), the noradrenaline reuptake inhibitor (NET), and the α_2A agonist — appearing on the map as directions on a lever, never as doses, drugs, or recommendations.

The crucial discipline is the one the whole frame turns on: a promoter read places a gene on a lever; it says nothing about whether raising or lowering that gene's activity is the therapeutic direction, or how far is too far, or in whom. Every one of the five drive-tone links is graded [O] cited biology, never derived from the substrate. The reuptake transporters carry a built-in honesty: a drive-tone lever modulates the tone of catecholamine signalling, which is a real and reachable handle, but it is the secondary axis — it does not reach down into how much transmitter the synthesis enzymes make or the SNARE machinery releases, which is the dominant fault and the subject of the next section. So the drive-tone levers are genuine, actionable directions on the reachable axis, and they are explicitly not a claim to have reached ADHD's core. A direction, never a dose — efficacy = 0.

The out-of-reach gain axis: synthesis, release, and a catabolic boundary

The dominant ADHD fault is the gain-amplitude (GA) axis — the §22 output / gain core — and it is exactly the axis a drive-tone lever cannot reach. The module names it with four real genes, each carried with its own promoter read alongside but explicitly not a lever. TH is tyrosine hydroxylase, the rate-limiting enzyme of catecholamine synthesis — it sets how much dopamine and noradrenaline is made, the amplitude itself. DBH is dopamine β-hydroxylase, which converts dopamine to noradrenaline — the second synthesis gain node. SNAP25 is the SNAP-25 SNARE protein of vesicle release — the presynaptic output gain, how much of what is made actually gets out. And COMT is catechol-O-methyltransferase, the prefrontal dopamine catabolism enzyme — carried as a boundary node, because clearance sits at the edge between amplitude and tone, but it is grouped with the gain axis because it sets how much signal remains rather than where the firing fold sits.

None of these is a lever, and the reason is mechanical: the catecholamine synthesis (TH, DBH), release (SNAP25) and catabolic-clearance (COMT) machinery sets signal amplitude, not the firing fold — and a drive-tone (reuptake / receptor) lever has no handle on synthesis or release. This is the direct analogue of autism's O axis (the synaptic output / gain deficit that a gain-reducing scalar push would only drive lower), and it is named here under the same discipline the autism chapter introduced: out-of-reach axes are carried on the map, by name, with real genes, so the partiality is concrete rather than hand-waved. The difference is that for autism the out-of-reach axes were the secondary ones — the chapter still reached autism's dominant excitability axis — whereas for ADHD the out-of-reach axis is the dominant one. That is the whole reason ADHD is a partial fit and autism was a clean one: the gain-amplitude core that defines ADHD sits on a different axis from the one the threshold frame can pull, and the module refuses to pretend otherwise. Each of the four genes is graded [F] NOT REACHED for the lever frame (axis-structured, not dose-structured), with its promoter γ read carried alongside as [V] structural context only.

Empty L1, empty L2, absent W — not a channelopathy, not a wiring disorder (the autism inverse)

Three of the four axes the frame can describe are, for ADHD, empty or absent, and each emptiness is a positive statement about what ADHD is not. L1 is empty — there is no inward-excitatory-current lever — and L2 is empty — there is no outward-potassium / inhibitory-current lever. Together that means ADHD is not a channelopathy: unlike epilepsy (which leaned on the M-current), bipolar (calcium channels), or autism (whose dominant lever was the inward excitatory current), ADHD has no ionic fold lever at all. There is no channel whose conductance you would change to raise or lower a firing threshold, because ADHD's fault is not a mis-set fold — it is a mis-set amplitude and tone. This is the second sense in which the fit is partial: the frame's structural [F] levers (the ionic ones) have nothing to grip, and the only handle is the [O] cited-biology drive surface. W is absent — zero wiring genes — because ADHD has intact long-range connectivity, the discriminant from autism.

Laid side by side, ADHD and autism are mirror images on this frame, and the contrast is the cleanest summary of both chapters. Autism was L1-dominant (its fault lived in the excitation/inhibition channels, the ionic fold), it reached its dominant axis, and it carried a W axis that was present and proven unreachable. ADHD is L3-only (its handle lives entirely in the up-stream drive, with the ionic levers empty), it misses its dominant axis (the gain core sits out of reach), and it carries no W axis at all (intact wiring). Autism is a channel-and-fold disorder whose wiring is broken but unreachable; ADHD is a drive-and-amplitude disorder whose wiring is intact and whose dominant amplitude core is out of the lever frame's reach. The [F] ionic structure that grounded autism is exactly what ADHD lacks, and the wiring fault that defined autism is exactly what ADHD does not have. Two disorders, one frame, opposite signatures — and the frame is honest about both, including its own partiality on ADHD.

The DNA grounding: a promoter's own switch stiffness, and a decoupling that inverts autism's

What places each of the nine genes — the five drive-tone levers and the four out-of-reach gain genes — is not a list but a read. For every gene, the module takes its promoter window (transcription start −2000 to +500 bases, Homo sapiens) and computes γ = −mean of the nearest-neighbour base-stacking free energies along that window (the SantaLucia 1998 nearest-neighbour thermodynamics), then turns that γ into the promoter's switch stiffness through the frozen engine's own functions: |h_sp| = spinodal(γ) = 2(γ/3)^1.5 and barrier = γ²/4. The reads span a real range. The five drive-tone levers, stiffest to softest, are the dopamine transporter SLC6A3 at γ ≈ 1.598 (|h_sp| ≈ 0.778), the D₄ receptor DRD4 (γ ≈ 1.577, |h_sp| ≈ 0.762), the serotonin transporter SLC6A4 (γ ≈ 1.516, |h_sp| ≈ 0.719), the α_2A receptor ADRA2A (γ ≈ 1.508, |h_sp| ≈ 0.712), and the noradrenaline transporter SLC6A2 (γ ≈ 1.462, |h_sp| ≈ 0.680). The four out-of-reach gain genes read TH at γ ≈ 1.538 (|h_sp| ≈ 0.734), DBH (γ ≈ 1.500, |h_sp| ≈ 0.707), COMT (γ ≈ 1.466, |h_sp| ≈ 0.683), and the SNARE release gene SNAP25 at γ ≈ 1.438 (|h_sp| ≈ 0.664, the softest in the whole set).

That range tells a story, and it is the exact inverse of autism's. In autism, promoter stiffness ran opposite to reachability: the genes a chemical lever could not touch (the out-of-reach scaffold and wiring genes) read stiffest, and the actionable E/I levers read softest. In ADHD the relationship flips: the stiffest promoter in the entire set, the dopamine transporter SLC6A3 (|h_sp| ≈ 0.778), is a reachable drive-tone lever — the canonical stimulant target — while the softest, the SNARE release gene SNAP25 (|h_sp| ≈ 0.664), is an out-of-reach gain gene. The genes the frame can touch read stiffest; the genes it cannot read softest — the opposite of autism. These are read on the same R19 substrate, with the same engine, that the bipolar, epilepsy, depression, schizophrenia, autism and analgesic packages used, which is the whole point of the inheritance: one substrate, one pipeline, now six problems. And the γ read is a property of the gene's promoter sequence, blind to whether the gene is on or off and to gain / loss / expression level — that is all it is, and it is the reason the next section's ranking can carry γ alongside every target without ever letting it touch the score.

Ranking targets, the ADHD unmet-need signature, and the firewall that adds two misuse guards

The last component prioritises, and it prioritises targets, never drugs or doses. Unlike autism — which ranked only its lever genes — the ADHD ranking spans all nine genes (the five levers and the four out-of-reach gain genes), precisely so the partiality is visible in the ranking itself. A burden-weighted score combines three declared, cited weights — clinical burden (0.40), unmet need (0.35), and genetic-evidence / druggability (0.25) — on cited 1–5 tiers. The ADHD signature is the inverse of autism's, and it shows up in the unmet-need tier. Autism had no approved core-feature pharmacology, so its unmet-need floor was the highest in the series and need was uniformly high. ADHD is the opposite: it has established, effective core routes — the dopamine transporter (methylphenidate / amphetamine), the noradrenaline transporter (atomoxetine), and the α_2A receptor (guanfacine) — so the reachable drive-tone transporters carry low unmet need, the lowest floor in the whole series. The out-of-reach gain genes (TH, DBH, SNAP25) carry the unmet-need ceiling — nothing selectively reaches the synthesis / release core — but they are flagged not actionable, because ranking a target you have already declared out of reach as a next step would be incoherent.

The consequence is a ranking that itself encodes the partial fit. The highest-burden, highest-unmet targets — TH first, then DRD4, DBH, SNAP25 — are all non-actionable: the synthesis / release gain genes because they are out of the lever frame's reach, and DRD4 because there is no selective agent for it. The leading actionable target is the dopamine transporter SLC6A3 — but only at rank five, lowered by its established-route low unmet need. In other words, where the unmet need is highest the target is unreachable, and where the target is reachable the unmet need is lowest — the signature of a disorder whose treatments work on the secondary axis while the dominant axis stays out of reach. This also produces the firewall made visible. The γ read is carried alongside each target as structural context but is never folded into the score, and the two rankings are decoupled: the stiffest promoter in the set, the dopamine transporter SLC6A3 (|h_sp| ≈ 0.778), sits at priority #5, not the top; and the top-priority target, the synthesis enzyme TH, has only the third-stiffest read. This is the inverse of autism's decoupling (where the stiffest read sat at the bottom of priority), and it makes the same point: if promoter stiffness drove the ranking, neither target could sit where it does.

A fail-closed forbidden-claim scanner guards the whole package, and for ADHD it is the strictest in the series. Beyond the usual dose / efficacy-as-fact / safety-as-fact / synthesis classes, it adds two classes specific to a stimulant topic. The stimulant-misuse class rejects get-high, snort, euphoria, recreational and party-drug vocabulary outright, because a stimulant mechanism map must never read as a misuse guide. The cognitive-enhancement class rejects smart-drug, study-drug, nootropic, boost-focus and limitless framing, because the map describes a disorder mechanism, not a performance aid for anyone. Both classes are negation-guarded — a sentence that rejects a misuse frame is allowed, a sentence that asserts one fails the build — and each carries a planted self-test that must fire on its own bait, failing the build if it ever does not. The firewall must be stated once more in full: the promoter |h_sp| is a gene's own switch stiffness, and it is never equated with a transporter occupancy, a synaptic catecholamine level, a stimulant's potency, a dose, an in-vivo selectivity, or any clinical effect. This module reproduces bit-for-bit with the engine byte-unchanged.

Discipline: a direction, never a dose — and not medical advice

Everything here is an in-silico reading of promoter sequence and a frame for organising targets, not a clinical measure, a diagnosis, or a prescription. The model asserts mechanism directions and target placements — ADHD's drive-tone set-point can be modulated through the up-stream drive lever; these five transporter and receptor genes populate that lever; ADHD loads its entire threshold-frame engagement on L3, with the ionic levers empty; the map reaches the secondary drive-tone axis only; the dominant gain-amplitude axis (synthesis, release, clearance) is named and out of reach; the wiring axis is absent; the fit is therefore the first [L] partial fit in the series — and nothing about which agent acts on any lever, at what dose, in whom, whether any real compound changes anyone's traits, or that anyone should change anything. The agents named as directions (the stimulant, atomoxetine and guanfacine arms) are illustrations of a sign on the reachable axis, never a recommendation, and the recorded structure — the dominant axis out of reach, the empty ionic levers, the absent wiring axis — is there precisely because a generic lever placement is not a clinical direction. Real ADHD is heterogeneous, and its dominant fault is an amplitude axis this lever frame explicitly cannot reach — a partiality that is locked, not smoothed over.

Two stricter boundaries close the chapter. ADHD is a difference in regulation — of attention, arousal, and drive — not a deficit of worth, intelligence, or character; the map ranks where a clean unmet mechanistic direction exists, and it does not assert that any direction treats, normalises, or cures ADHD, nor that anyone should be made to conform. And nothing in the stimulant biology described here is a licence for misuse or enhancement: the map is a disorder-mechanism frame, the scanner rejects get-high / recreational and smart-drug / nootropic framing outright, and the agents named as directions are mechanism signs, never performance aids. A promoter read and a lever assignment are mechanism boundaries, not a claim about the felt quality of an ADHD mind (Axis-A firewall — consciousness_claim = 0, the hard problem stays open). This is not medical advice, not a diagnosis, not a treatment protocol, and not a cure. medium_efficacy_tested = 0; targets ranked, never drugs or doses; no stimulant-misuse or cognitive-enhancement licence.